A Randomised Study to compare intravenous Labetalol versus Lignocaine for Attenuation of Hemodynamic response to Laryngoscopy and Endotracheal intubation in ,SMS Medical college,Jaipur. - NIL

Start Date05 Jan 2026

Sponsor / Collaborator

SMS Medical College - India

CTRI/2025/12/099566

/ Not yet recruitingPhase 3IIT

A randomized trial comparing the efficacy of labetalol versus dexmedetomidine for attenuation of hemodynamic stress response in patients undergoing double lumen tube insertion. - NIL

Start Date31 Dec 2025

Sponsor / Collaborator-

CTRI/2025/12/098924

/ Not yet recruitingNot ApplicableIIT

A Randomized Study to Compare the Effect of Two Different Doses of Intravenous Labetalol for Attenuation of Hemodynamic Response During Endotracheal Extubation in Laparoscopy Cholecystectomy Under General Anaesthesia at SMS Medical College Jaipur. - NIL

Start Date24 Dec 2025

Sponsor / Collaborator

SMS Medical College - India

100 Clinical Results associated with Labetalol Hydrochloride

100 Translational Medicine associated with Labetalol Hydrochloride

100 Patents (Medical) associated with Labetalol Hydrochloride

3,330

Literatures (Medical) associated with Labetalol Hydrochloride

01 Mar 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Outcomes of a blood pressure control protocol for intracerebral hemorrhage in the emergency department

Article

Author: Koch, Sebastian ; Ancheta, Selina ; Fee, Taylor ; Mckinley, Kelly ; Krenz, James

BACKGROUND:

Spontaneous intracerebral hemorrhage is a neurologic emergency associated with high morbidity and mortality. Acute blood pressure management is a modifiable factor shown to influence clinical outcomes. To address this outcome, a standardized blood pressure algorithm was integrated into an institutional ICH alert protocol to optimize timely antihypertensive therapy in the emergency department.

METHODS:

This single-center, retrospective observational study evaluated adult emergency department patients diagnosed with spontaneous intracerebral hemorrhage between August 2023 and March 2025. Outcomes compared pre-and post-protocol implementation and a per protocol group, with a primary objective of time from ICH alert activation to achievement of goal blood pressure. Secondary outcomes included medication administration times, protocol adherence, safety outcomes, and the impact of clinical pharmacist involvement.

RESULTS:

Seventy-seven patients met inclusion criteria (35 pre-protocol, 42 post-protocol), with 32 managed per protocol. Median time from ICH alert to systolic blood pressure goal decreased from 88 to 78 min (absolute reduction 10 min) post-protocol and to 55 min (absolute reduction 33 min) in the per-protocol subgroup (p = 0.012). Labetalol-nicardipine combination therapy was significantly faster in achieving blood pressure goals compared to nicardipine monotherapy (p < 0.001). Protocol deviations occurred in 55 % of post-protocol cases. Safety outcomes, including hypotension and bradycardia, were infrequent.

CONCLUSION:

In this single-center study, implementation of a standardized blood pressure management protocol for an ICH alert improved time to systolic blood pressure control when fully adhered to. Use of labetalol first, followed by nicardipine, was associated with faster intervention. These findings support protocolized, multidisciplinary approaches for improving acute ICH care.

01 Feb 2026·BLOOD PRESSURE MONITORING

Effect of nifedipine combined with magnesium sulfate on gestational hypertension and its impact on blood lipids

Article

Author: Li, Hengjing ; Xing, Shaoning ; Cheng, Hong ; Fu, Aizhen

Objective:

This study aimed to evaluate the efficacy of nifedipine combined with magnesium sulfate in pregnant women with gestational hypertension (GH) and its influence on blood lipid levels.

Methods:

Seventy pregnant women with GH were randomly assigned to either a control group (labetalol plus magnesium sulfate) or an observation group (nifedipine extended-release tablets plus magnesium sulfate) ( n = 35). Both groups were treated for 7 days. Posttreatment, changes in blood pressure (SBP and DBP), hemorheological parameters [whole blood high-shear viscosity, low-shear viscosity, plasma viscosity (PV)], blood lipid levels [high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and total cholesterol (TC)], adverse reactions, and pregnancy outcomes were assessed.

Results:

Posttreatment, both groups showed significant reductions in SBP and DBP, with greater decreases in the observation group ( P < 0.05). After 7 days of treatment, whole blood high-shear viscosity, low-shear viscosity, and PV decreased in both groups, with lower values for these in the observation group ( P < 0.05). Lipid profiles improved in both groups, with the observation group showing higher HDL-C and lower LDL-C, TG, and TC ( P < 0.05). The observation group had a higher overall efficacy rate (94.29 vs. 77.14%, P < 0.05) and fewer adverse pregnancy outcomes (8.57% vs. 28.57%, P < 0.05), while the incidence of adverse reactions was comparable between groups.

Conclusion:

Nifedipine combined with magnesium sulfate is more effective in managing GH. This regimen better improves blood pressure, hemorheological parameters, lipid profiles, and pregnancy outcomes, with good safety.

01 Jan 2026·JOURNAL OF HYPERTENSION

Modulation of blood pressure in pregnant rats through probiotic-fermented buffalo milk, propionate-producing bacteria, and the phenylalanine metabolic pathway

Article

Author: Li, Xia ; Dong, Xin-Hong ; Jiang, Tie-Min ; Li, Hai-Yun ; Chen, Si-Ting ; Lu, Huan-Zhao ; Khoo, Hock Eng

Objective::

Pregnancy-induced hypertension (PIH) is a significant health concern affecting both maternal and fetal well-being, with limited effective interventions currently available. The objective of this study is to examine the relationship between stable blood pressure and changes in gut microbiota in pregnancy-induced hypertension (PIH) rats following treatment with probiotic-fermented buffalo milk (PBM).

Methods::

Twenty-four Sprague–Dawley pregnant rats were allocated into four groups: the normal control (NC) group, model control (MC) group, fermented buffalo milk (FBM) group, and labetalol positive control (LPC) group. Rats in the FBM and LPC groups received oral gavage with PBM at a dose of 20 mg/kg/day and labetalol hydrochloride (LH) at 4 mg/kg/day, respectively, from the first day of pregnancy until day 21. Rats in the NC and MC groups were administered an equivalent volume of saline (10 ml). Pregnancy-induced hypertension was established by subcutaneous injection of l -nitro-arginine methyl ester daily from day 15 to day 21 of pregnancy. Blood pressure was monitored regularly across all groups, and differences in gut microbiota composition and functional activity were analyzed using high-throughput 16S rRNA sequencing and metabolomic profiling.

Results::

PBM demonstrated a superior ability to stabilize blood pressure in pregnant rats compared to LH. PBM modulated the gut microbiota by increasing the relative abundance of propionate-producing bacteria, including Fusobacterium , Lachnospira , and Roseburia . Additionally, PBM reduced phenylalanine metabolism, thereby inhibiting the production of phenylacetylglycine, a metabolite associated with hypertension.

Conclusion::

The blood pressure-lowering effect of PBM in PIH rats may be associated with the regulation of propionate-producing bacteria and their metabolic functions.

News (Medical) associated with Labetalol Hydrochloride

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

03 Sep 2024

·www.pharmaceutical-technology.com

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

At the ESC Congress, Dr. Milton Packer highlighted recent research into beta blocker treatment for myocardial infarction. Credit: luchschenF via Shutterstock. A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held from 31 August to 2 September. Over the past 40 years, the research space has operated on an understanding that immediate inhibition by beta-blockers reduces left ventricular rupture, and further myocardial infarction , said Dr. Milton Packer, distinguished scholar in cardiovascular science at Baylor University Medical Center, Dallas. Additionally, the belief was that delayed long-term blockade can lead to left ventricular dysfunction, he said. Beta-blockers are a class of drugs that act by inhibiting the actions of hormones such as adrenaline to slow down the heart. Commonly used beta blockers include Abbott ’s Tenormin (atenolol), MSD’s Cardicor (bisoprolol), and GSK ’s Trandate (labetalol). However, Packer explained that the beta blocker response has changed as percutaneous interventions, reperfusion therapies, antiplatelet drugs and more have entered the treatment landscape for myocardial infarction. At the ongoing ESC Congress talk titled “Should we give beta blockers post-myocardial infarction?” Packer said that questions have been raised surrounding the use of the drugs in patients with myocardial infarction and preserved ejection fraction, referencing the Phase IIII REDUCE-AMI study (NCT03278509). See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication REDUCE-AMI, which was funded by the Swedish Research Council, tested the use of beta-blockers after myocardial infarction and preserved ejection fraction. The study found that for patients with acute myocardial infarction who underwent early coronary angiography and had preserved left ventricular ejection fraction, long-term beta-blocker treatment did not lower the risk of death from any cause or new myocardial infarctions compared to no beta-blocker use. Despite the conclusion of the REDUCE-AMI study, Packer highlighted the fact that researchers have only investigated and proven the effectiveness of non-selective beta blockers in post-myocardial infarction trials, so further research is required. He added that physicians will have to take into account the degree of beta-blockade in future treatment regimens.

VaccinePhase 3Drug ApprovalClinical Result

17 Jun 2024

·www.drugs.com

2008 to 2021 Saw Increase in Prevalence of Chronic HTN in Pregnancy

MONDAY, June 17, 2024 -- For pregnant individuals, the prevalence of chronic hypertension more than doubled between 2008 and 2021, according to a study published online June 17 in Hypertension . Stephanie A. Leonard, Ph.D., from the Stanford University School of Medicine in California, and colleagues analyzed commercial insurance claims from 2007 to 2021 and assessed the prevalence of chronic hypertension during pregnancy and trends in oral antihypertensive medication use. The researchers found that between 2008 and 2021, the prevalence of chronic hypertension increased steadily from 1.8 to 3.7 percent among 1,900,196 pregnancies. During the study period, antihypertensive medication use among those with chronic hypertension was relatively stable (57 to 60 percent). There was a decrease seen in the proportion of pregnant individuals with chronic hypertension treated with methyldopa or hydrochlorothiazide (from 29 to 2 percent and from 11 to 5 percent, respectively), and there was an increase seen in the proportion treated with labetalol or nifedipine (from 19 to 42 percent and from 9 to 17 percent, respectively). Following the 2017 American College of Cardiology and American Heart Association hypertension guidelines, there was no change observed in the prevalence or treatment of chronic hypertension during pregnancy. "There were large shifts in the medications used to treat chronic hypertension in pregnancy, with labetalol supplanting methyldopa as the most commonly used antihypertensive medication," the authors write. One author disclosed ties to the pharmaceutical industry.

AHAClinical Study

100 Deals associated with Labetalol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00600	Labetalol Hydrochloride	C07AG01	DB00598

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Schering Corp.	01 Aug 1984
Hypertension	United States	Alvogen, Inc.	01 Aug 1984
Essential Hypertension	Japan	Sandoz AG	07 Oct 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04343235 (CTgov)	Phase 4	Hypertension, Pregnancy-Induced \| Pre-Eclampsia	13	labetalol+furosemide (Labetalol + Furosemide)	ysbigyjoij = cwxigcbfre pibhwpdbbj (mtdktgzdvz, tkadkiyhky - jtyaqxhmep) View more	-	23 Oct 2023
				labetalol (Labetalol Only)	ysbigyjoij = kbhhitiicv pibhwpdbbj (mtdktgzdvz, qfzsfqnapi - yokondmhxf) View more
NCT04116112 (BEST-II, CTgov)	Phase 2	Thrombosis \| Stroke	120	Labetalol+Nicardipine+Hydralazine (Higher Systolic Blood Pressure (SBP) Target)	hjdtvovkjb(gqklkqgycj) = kcnyltgxkr ikipkvthrc (fwlqhgbftc, ggzwdtxekh - sxlvfxovaf) View more	-	12 Oct 2023
				Labetalol+Nicardipine+Hydralazine (Lower SBP (<160 mmHg) Target)	hjdtvovkjb(gqklkqgycj) = cqghmthvcp ikipkvthrc (fwlqhgbftc, lkixpeduol - efqaxofnwq) View more
NCT04539379 (ZU-IRB#: 6353-23-3-2020, Pubmed \| J Clin Monit Comput)	Not Applicable	Pre-Eclampsia	-	Magnesium sulfate	lldwqerwoq(frxtgrjneu) = coltikxcvz wbbgsqdmqb (tlqzfwzciq )	Positive	01 Aug 2023
				Labetalol	lldwqerwoq(frxtgrjneu) = uxseeyrkej wbbgsqdmqb (tlqzfwzciq )
NCT03506724 (CTgov)	Phase 4	Pre-Eclampsia	109	Labetalol (Intravenous Labetalol)	dqklyuqgiz(vxtaqwlrve) = tyhumduwbj hiubgdjqhj (jpgaszfszv, yrrftlsizm - suovswwfuj) View more	-	24 May 2021
				Nifedipine (Oral Nifedipine)	dqklyuqgiz(vxtaqwlrve) = huqmgfvbtx hiubgdjqhj (jpgaszfszv, kicuupjzxk - hzsokgjzba) View more
NCT01114971 (CTgov)	Phase 4	Pain, Postoperative	75	Esmolol+Labetalol (Fentanyl)	evgmsnhsll(oagnsnyojn) = adwrfhhnxy ybbxhjcoce (fqkruvejpo, 2) View more	-	20 Feb 2020
				Fentanyl+Esmolol (Labetalol)	evgmsnhsll(oagnsnyojn) = jwehpgrrjc ybbxhjcoce (fqkruvejpo, 3) View more
NCT02168309 (CTgov)	Not Applicable	Hypertension	50	Labetalol (Labetalol)	ncrtsefxrx(usthfnbuxl) = emkacjqetn xljwjamyvj (bejkfbvclq, 32.5) View more	-	13 Dec 2017
				Nifedipine (Nifedipine)	ncrtsefxrx(usthfnbuxl) = knhbhdzlym xljwjamyvj (bejkfbvclq, 27.6) View more
ISRCTN40973936 (Pubmed \| Hypertension)	Not Applicable	Hypertension, Pregnancy-Induced First line	112	Labetalol	mwbvjlumky(cnwknttauk) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis snvlqnpxdu (ugmyfbhjgm )	-	01 Nov 2017
				Nifedipine-modified release
NCT02168309 (Pubmed \| Hypertens Pregnancy)	Not Applicable	Hypertension	50	Oral labetalol	hiaeosgdgo(ezvxmokypr) = utodxgqeeb sqgagnewbo (fweolrseaf )	-	02 Jan 2017
				Oral extended release nifedipine	hiaeosgdgo(ezvxmokypr) = fliettxynz sqgagnewbo (fweolrseaf )
NCT00765648 (CLUE trial \| CLUE, CTgov)	Phase 4	Hypertension	226	Nicardipine (Nicardipine)	gdpekusduw = attqkzexjc ltqzajcffw (gixevakdlk, uyxstuktga - yzgmhnakrk) View more	-	11 Dec 2014
				Labetalol (Labetalol)	gdpekusduw = ulilqmlyzb ltqzajcffw (gixevakdlk, bvoyfpccdc - aagtiuxupx) View more
NCT01041066 (Pubmed \| Clin Ther)	Not Applicable	Hypertension	130	Nicardipine 20 μg/kg IV	swouevueaw(ymfrcqczbz) = quyarrncpu abtnvmxdvv (rtqbxrngun )	-	01 Mar 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Labetalol Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation